Ian Flinn, MD, PhD

Ian Flinn, MD, PhD, describes some of the important unmet needs of DLBCL, particularly in R/R DLBCL, and shares his hopes for the future of treatment.

An oncologist shares which treatment regimen he would recommend next for this patient with DLBCL who experienced two disease relapses and reflects on how CD19- and CD79b-targeted therapies have impacted patient outcomes in the field.

Dr Ian Flinn explains the available treatment options for patients with DLBCL who experience 2 or more relapses, and the situations in which he would use each regimen.

An expert provides his perspective on the first- and second-line treatment approaches in the patient case and comments on the patient’s likely prognosis.

Ian Flinn, MD, PhD, presents the case of a 68-year-old man with diffuse large B-cell lymphoma (DLBCL) and 2 relapses after complete disease remission.

Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.<br /> &nbsp;